Intra-Cellular Therapies: These Are 5 Critical Challenges Threatening Its Expansion Plans!

Intra-Cellular Therapies’ latest earnings results highlight a continued positive growth trajectory, driven primarily by the strong performance of its flagship drug, CAPLYTA (lumateperone). The company reported $175.2 million in net sales for CAPLYTA during the third quarter of 2024, reflecting a notable 39% increase compared to the same period last year. This growth outpaced the overall antipsychotic market, underscoring CAPLYTA’s growing acceptance and market share, particularly in the treatment of bipolar depression.